Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ALXN 2420

Next Previous
Drug Profile

ALXN 2420

Alternative Names: ALXN-2420; AZP-3813

Latest Information Update: 11 May 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator PeptiDream
  • Developer Amolyt Pharma
  • Class Bicyclic peptides; Macrocyclic compounds; Peptides
  • Mechanism of Action Somatotropin receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Acromegaly

Most Recent Events

  • 31 Mar 2026 Discontinued - Phase-II for Acromegaly (Combination therapy) in Lithuania, Romania, Italy, Brazil, Argentina, China, Denmark, Hungary, Poland, Netherlands, USA (SC), due to strategic reasons (AstraZeneca pipeline, May 2026)
  • 31 Mar 2026 Alexion Pharmaceuticals terminates the phase-II ASTERIA trial for Acromegaly (Combination therapy) in Lithuania, Romania, Italy, Brazil, Argentina, China, Denmark, Hungary, Poland, Netherlands, USA (SC), due to strategic reasons (AstraZeneca pipeline, May 2026) (NCT07037420)
  • 28 Oct 2025 Phase-II clinical trials in Acromegaly (Combination therapy) in USA, Argentina, Italy, Lithuania, Romania (SC) (NCT07037420)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top